EP0851759A4 - Compounds and methods - Google Patents

Compounds and methods

Info

Publication number
EP0851759A4
EP0851759A4 EP96930743A EP96930743A EP0851759A4 EP 0851759 A4 EP0851759 A4 EP 0851759A4 EP 96930743 A EP96930743 A EP 96930743A EP 96930743 A EP96930743 A EP 96930743A EP 0851759 A4 EP0851759 A4 EP 0851759A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96930743A
Other languages
German (de)
French (fr)
Other versions
EP0851759A1 (en
Inventor
Robert A Daines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0851759A1 publication Critical patent/EP0851759A1/en
Publication of EP0851759A4 publication Critical patent/EP0851759A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96930743A 1995-09-05 1996-09-05 Compounds and methods Withdrawn EP0851759A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US355695P 1995-09-05 1995-09-05
PCT/US1996/014347 WO1997009046A1 (en) 1995-09-05 1996-09-05 Compounds and methods
US3556P 1996-12-30

Publications (2)

Publication Number Publication Date
EP0851759A1 EP0851759A1 (en) 1998-07-08
EP0851759A4 true EP0851759A4 (en) 2000-12-06

Family

ID=21706424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96930743A Withdrawn EP0851759A4 (en) 1995-09-05 1996-09-05 Compounds and methods

Country Status (3)

Country Link
EP (1) EP0851759A4 (en)
JP (1) JPH11512396A (en)
WO (1) WO1997009046A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
MXPA04011960A (en) 2002-06-05 2005-03-31 Squibb Bristol Myers Co Calcitonin gene related peptide receptor antagonists.
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
EP1641781B1 (en) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
CN100558428C (en) 2003-12-05 2009-11-11 布里斯托尔-迈尔斯·斯奎布公司 Calcitonin gene related peptide receptor antagonists
AR046787A1 (en) 2003-12-05 2005-12-21 Bristol Myers Squibb Co HETEROCICLIC ANTIMIGRAN AGENTS
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7696192B2 (en) * 2004-09-09 2010-04-13 Merck Sharp & Dohme Corp. Tricyclic anilide spirolactam CGRP receptor antagonists
EP1794146B1 (en) * 2004-09-13 2011-08-03 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin cgrp receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
ES2664854T3 (en) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against a peptide related to the calcitonin gene to treat cluster headache
CN101959528A (en) 2008-03-04 2011-01-26 辉瑞有限公司 Methods of treating chronic pain
UA105182C2 (en) 2008-07-03 2014-04-25 Ньюрексон, Інк. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JP2013533310A (en) 2010-08-09 2013-08-22 ユニバーシティー オブ メリーランド，ボルティモア Method for treating obstructive pulmonary disease using bitter substances
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
DK2709663T3 (en) 2011-05-20 2019-05-20 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or aversion to light in individuals in need thereof, especially migraineurs
RS61793B1 (en) 2011-05-20 2021-06-30 H Lundbeck As Anti-cgrp compositions and use thereof
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
SI3119431T1 (en) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10888552B2 (en) 2016-08-12 2021-01-12 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
CN109952314A (en) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 Treat intractable migraine
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA873893A (en) * 1971-06-22 P. Yardley John Cinchona alkaloid derivatives
US3929795A (en) * 1968-07-02 1975-12-30 Hoffmann La Roche Processes and intermediates for quinine, quinidine, isomers and derivatives thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAINES R A ET AL: "Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 20, 21 October 1997 (1997-10-21), pages 2673 - 2676, XP004136510, ISSN: 0960-894X *
See also references of WO9709046A1 *

Also Published As

Publication number Publication date
EP0851759A1 (en) 1998-07-08
WO1997009046A1 (en) 1997-03-13
JPH11512396A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
GB2298422B (en) Compounds and their use
IL117177A0 (en) Benzopyran-containing compounds and method for their use
EP0851759A4 (en) Compounds and methods
EP0836617A4 (en) Parevins and tachytegrins
HU9601680D0 (en) Benzisothiazolyl-substituted aminomethyl-chromanes
DE59602888D1 (en) Breitstreckaggregat
DE59602283D1 (en) Inchbremseinrichtung
DE59602030D1 (en) Zellige polyurethan-elastomere
EP0799225A4 (en) Compounds and methods
GB9616563D0 (en) Compounds and methods
GB9504876D0 (en) Compounds and process
GB9525234D0 (en) Process compound and use
AP9600802A0 (en) Libricant
DE59604506D1 (en) Rückkühlsystem
GB9722556D0 (en) Methods
EP0934345A4 (en) Compounds and methods
DE59604913D1 (en) Carbonylverbindungen
AU1105P (en) DALESE Metrosideros excelsus
GB9516970D0 (en) Methods
GB9516940D0 (en) Methods
GB9510639D0 (en) Methods
GB9505905D0 (en) Methods
GB9523379D0 (en) Compound and method
AU126858S (en) Billycart
AU126739S (en) Gamesboard

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20001024

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010109